Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group.
暂无分享,去创建一个
M. Martín | F. Rivera | R. Pazo-Cid | M. Benavides | E. Aranda | R. Vera | A. Irigoyen | J. Gallego | S. Arévalo | A. Sáenz | V. Iranzo | L. López Gómez | I. Alés | A. Hurtado | A. Salud | E. Falcó | Ò. Serra | G. Pulido | T. García García | C. Guillén Ponce | E. Martínez Ortega | J. Martínez Galán | A. Pisa | E. F. Fernández Parra | M. J. Gómez Reina | J. L. Manzano Mozo
[1] P. Murawa,et al. Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] A. Farioli,et al. Membrane Localization of Human Equilibrative Nucleoside Transporter 1 in Tumor Cells May Predict Response to Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients. , 2016, The oncologist.
[3] T. Gauler,et al. Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: A subgroup analysis from AIO-PK0104 , 2015, Acta oncologica.
[4] E. Van Cutsem,et al. Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study , 2014, British Journal of Cancer.
[5] D. Yoon,et al. Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer , 2014, Cancer research and treatment : official journal of Korean Cancer Association.
[6] A. Carrato,et al. TTD consensus document on the diagnosis and management of exocrine pancreatic cancer , 2014, Clinical and Translational Oncology.
[7] Stephen L. Chan,et al. Systemic treatment for inoperable pancreatic adenocarcinoma: review and update , 2014, Chinese journal of cancer.
[8] David Goldstein,et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.
[9] C. Cass,et al. Erlotinib, Gefitinib, and Vandetanib Inhibit Human Nucleoside Transporters and Protect Cancer Cells from Gemcitabine Cytotoxicity , 2013, Clinical Cancer Research.
[10] M. Valladares-Ayerbes,et al. Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study). , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] Pierre Michel,et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.
[12] C. Mathers,et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.
[13] T. Gauler,et al. Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’ , 2010, Anti-cancer drugs.
[14] Y. Bang,et al. A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research , 2009, Investigational New Drugs.
[15] E. Van Cutsem,et al. Rash as a marker for the efficacy of gemcitabine plus erlotinib-based therapy in pancreatic cancer: Results from the AViTA Study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] W. Scheithauer,et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Godefridus J Peters,et al. Gemcitabine chemoresistance in pancreatic cancer: Molecular mechanisms and potential solutions , 2009, Scandinavian journal of gastroenterology.
[18] W. Scheithauer,et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Renato Martins,et al. Erlotinib in previously treated non-small-cell lung cancer. , 2005, The New England journal of medicine.
[20] D. V. Von Hoff,et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] A. Jemal,et al. Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.
[22] C. Mathers,et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer , 2013 .